The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Long-term effects of treatment of central precocious puberty with gonadotropin-releasing hormone analogs every three months.

TitleLong-term effects of treatment of central precocious puberty with gonadotropin-releasing hormone analogs every three months.
Publication TypeJournal Article
Year of Publication2020
AuthorsVatopoulou, A., Roos E., Daniilidis A., & Dinas K.
JournalGynecol Endocrinol
Volume36
Issue12
Pagination1124-1126
Date Published2020 Dec
ISSN1473-0766
Abstract

BACKGROUND: Gonadotropin-releasing hormone (GnRH) analogs represent the treatment of choice in patients with central precocious puberty (CPP). Recently, GnRH analogs that can be administered every 3 months have been developed and appear to be as safe and effective as one-monthly formulations. However, there are limited data regarding its long term safety and efficacy profile. We aimed to evaluate the long-term safety and efficacy treatment of CPP with GnRH analogs every 3 months.METHODS: We prospectively studied all patients who were diagnosed with CPP in our center between January 2015 and December 2019. All patients were treated with intramuscular leuprolide acetate 11.25 mg every 3 months.RESULTS: Twenty-four patients with CPP were included in the study. Mean follow-up was 3.1 years. Height gain ranged between 4 and 6 cm. Bone mineral density (BMD) was not affected. Body mass index (BMI) increased in all subjects but none was obese at the end of follow-up.CONCLUSIONS: Treatment of patients with CPP with GnRH analogs every 3 months induces substantial increases in height and does not affect BMI or BMD. Therefore, it represents an attractive option for these young patients.

DOI10.1080/09513590.2020.1770723
Alternate JournalGynecol Endocrinol
PubMed ID32484003

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.